Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients

Clinical and Experimental Pharmacology and Physiology

Volumn 29, Issue 10, 2002, Pages 891-897

  Arruzazabala, María Lourdes ^a   Molina, Vivian ^a   Mas, Rosa ^a   Fernández, Lilia ^a   Carbajal, Daisy ^a   Valdés, Suria ^a   Castaño, Gladys ^b  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Surgical Medical Research Center   (Cuba)

Author keywords

Antiplatelet drugs; Healthy volunteers; Hypercholesterolaemia; Platelet aggregation; Policosanol

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; REDUCTION; TASK PERFORMANCE; THROMBOCYTE AGGREGATION;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STATISTICS, NONPARAMETRIC;

EID: 0036049409     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2002.03746.x     Document Type: Article

References (52)

1. Platelet-endothelial interactions in atherothrombotic disease: Therapeutic implications
2. Collaborative overview of randomized trials antiplatelet therapy I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
3. European and American recommendations for coronary heart disease prevention
4. Policosanol
5. Effects of policosanol on serum lipids and lipoproteins in healthy volunteers
6. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
7. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment
8. Effect of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemia
9. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia
10. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia
11. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
12. A comparative study of policosanol vs acipimox in patients with type II hypercholesterolemia
13. Effect of policosanol on postmenopausal women with type II hypercholesterolemia
14. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors
15. Effects of policosanol and pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients
16. One year study on the effect of policosanol (5 mg twice-a-day) on lipid profile in patients with type II hypercholesterolemia
17. A two years study on the efficacy and tolerability of policosanol in patients with type II hypercholesterolemia
18. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12 months study
19. Effects of policosanol on primary hypercholesterolemia: A 3-year open follow-up
20. Open-label study of the efficacy, safety and tolerability of policosanol in patients with high global coronary risk
21. Comparison of two regimens of policosanol administered at 20 mg/d in patients with type II hypercholesterolemia: A randomized, double-blind, double-dummy study
22. A long-term open study of the efficacy and tolerability of policosanol in patients with high global coronary risk
23. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: A 6 months double-blind study
24. Treatment of hypercholesterolemia in NIDDM with policosanol
25. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia
26. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus
27. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts
28. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet
29. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts
30. Estudio farmacológico de la interacción entre el policosanol y la aspirina en animales de experimentación
31. Effects of policosanol on platelet aggregation in rats
32. 2
33. Effect of policosanol on experimental thrombosis models
34. Effect of policosanol on platelet aggregation in healthy volunteers
35. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
36. Efecto del policosanol sobre la función de las plaquetas en voluntarios sanos
37. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers
38. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients
39. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
40. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death
41. Aggregation of blood platelets by adenosine diphosphate and its reversal
42. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstat and magnesium chloride
43. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge
44. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
45. Statistical considerations for performing multiple tests in a single experiment 5. Comparing two therapies with respect to several endpoints
46. Antiplatelet therapy
47. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents
48. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
49. Estudio comparativo de la eficacia y tolerabilidad del policosanol, la simvastatina y de su terapia combinada en el tratamiento de la Hipercolesterolemia tipo II
50. Comparative study of policosanol, aspirin and the combination policosanol-aspirin on platelet aggregation in healthy volunteers
51. Policosanol. Results of a postmarketing surveillance control on 27 879 cases